CD274 and renal cell adenocarcinoma: Indeed, in Immotion150 305 patients with locally advanced/mRCC and untreated RCC were randomized to receive: atezolizumab (an anti PD-L1 inhibitor) and bevacizumab, atezolizumab alone or sunitinib (41).